Mark Lance Shibuya

Array ( [id] => 19031485 [patent_doc_number] => 20240081300 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => ADRENERGIC MECHANISMS OF AUDIOGENIC SEIZURE-INDUCED DEATH IN MOUSE MODEL OF SCN8A ENCEPHALOPATHY [patent_app_type] => utility [patent_app_number] => 18/271911 [patent_app_country] => US [patent_app_date] => 2022-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24980 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18271911 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18955467 [patent_doc_number] => 20240043794 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => Chemically Defined Serum Albumin Substitutes [patent_app_type] => utility [patent_app_number] => 18/257534 [patent_app_country] => US [patent_app_date] => 2021-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21157 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -59 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18257534 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18923305 [patent_doc_number] => 20240026309 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => CELL LINES FOR PRODUCTION OF ADENO-ASSOCIATED VIRUS [patent_app_type] => utility [patent_app_number] => 18/256530 [patent_app_country] => US [patent_app_date] => 2021-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10274 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18256530 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19345514 [patent_doc_number] => 20240254477 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => METHODS AND COMPOSITIONS FOR LINKING RNA STEM LOOPS [patent_app_type] => utility [patent_app_number] => 18/038190 [patent_app_country] => US [patent_app_date] => 2021-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59433 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18038190 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17444162 [patent_doc_number] => 20220064667 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => UNIVERSAL DONOR CELLS [patent_app_type] => utility [patent_app_number] => 17/531172 [patent_app_country] => US [patent_app_date] => 2021-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33601 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 155 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17531172 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18816079 [patent_doc_number] => 20230390418 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => VECTORIZED FACTOR XII ANTIBODIES AND ADMINISTRATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/034334 [patent_app_country] => US [patent_app_date] => 2021-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43482 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18034334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18817826 [patent_doc_number] => 20230392166 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => ANTI-APOPTOTIC VECTOR AND METHOD OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 18/250158 [patent_app_country] => US [patent_app_date] => 2021-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14348 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18250158 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18892975 [patent_doc_number] => 20240008460 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => JAK3 GENE-MUTATED, SEVERE COMBINED IMMUNODEFICIENCY ANIMAL MODEL AND CONSTRUCTION METHOD THEREFOR [patent_app_type] => utility [patent_app_number] => 18/034995 [patent_app_country] => US [patent_app_date] => 2021-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12380 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18034995 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18786430 [patent_doc_number] => 20230374541 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => RECOMBINANT ADENO-ASSOCIATED VIRUSES FOR CNS OR MUSCLE DELIVERY [patent_app_type] => utility [patent_app_number] => 18/030683 [patent_app_country] => US [patent_app_date] => 2021-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28330 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18030683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18808921 [patent_doc_number] => 20230383256 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => PROCESS FOR PRODUCING CULTURED RED BLOOD CELLS [patent_app_type] => utility [patent_app_number] => 18/246471 [patent_app_country] => US [patent_app_date] => 2021-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7521 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18246471 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18754383 [patent_doc_number] => 20230357795 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => AAV-MEDIATED HOMOLOGY-INDEPENDENT TARGETED INTEGRATION GENE EDITING FOR CORRECTION OF DIVERSE DMD MUTATIONS IN PATIENTS WITH MUSCULAR DYSTROPHY [patent_app_type] => utility [patent_app_number] => 18/245025 [patent_app_country] => US [patent_app_date] => 2021-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32662 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -74 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18245025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17273007 [patent_doc_number] => 20210379205 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => Use of Lyso-GB1 as Druggable Target [patent_app_type] => utility [patent_app_number] => 17/407558 [patent_app_country] => US [patent_app_date] => 2021-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17407558 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17227120 [patent_doc_number] => 20210353676 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => ENGINEERED LYMPHOCYTE COMPOSITIONS, METHODS AND SYSTEMS [patent_app_type] => utility [patent_app_number] => 17/373194 [patent_app_country] => US [patent_app_date] => 2021-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12863 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17373194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20414173 [patent_doc_number] => 12497443 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-16 [patent_title] => Systems and methods for the production of human polyclonal antibodies [patent_app_type] => utility [patent_app_number] => 17/363798 [patent_app_country] => US [patent_app_date] => 2021-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 92 [patent_no_of_words] => 19272 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 149 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17363798 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20357365 [patent_doc_number] => 12473348 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-18 [patent_title] => Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells [patent_app_type] => utility [patent_app_number] => 17/356423 [patent_app_country] => US [patent_app_date] => 2021-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 16 [patent_no_of_words] => 9896 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17356423 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20357364 [patent_doc_number] => 12473347 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-18 [patent_title] => Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells [patent_app_type] => utility [patent_app_number] => 17/356411 [patent_app_country] => US [patent_app_date] => 2021-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 16 [patent_no_of_words] => 10152 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17356411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20343145 [patent_doc_number] => 12466867 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-11 [patent_title] => Methods for activation and expansion of natural killer cells and uses thereof [patent_app_type] => utility [patent_app_number] => 17/304585 [patent_app_country] => US [patent_app_date] => 2021-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 6345 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17304585 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18391791 [patent_doc_number] => 20230160009 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => PREDICTIVE RESPONSE BIOMARKER DISCOVERY PROCESS [patent_app_type] => utility [patent_app_number] => 18/010044 [patent_app_country] => US [patent_app_date] => 2021-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14778 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18010044 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19389741 [patent_doc_number] => 20240279611 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => EXOSOME PRODUCTION PROMOTING AGENT AND EXOSOME PRODUCTION PROMOTING METHOD [patent_app_type] => utility [patent_app_number] => 18/568061 [patent_app_country] => US [patent_app_date] => 2021-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3195 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18568061 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18497680 [patent_doc_number] => 20230220349 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => 3D CULTURE OF MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS [patent_app_type] => utility [patent_app_number] => 18/001462 [patent_app_country] => US [patent_app_date] => 2021-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17042 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001462 [rel_patent_id] =>[rel_patent_doc_number] =>)